Akebia Therapeutics (AKBA) Stock Price, Quote & News

Latest News on AKBA

Jan 13, 2025, 8:00 AM EST - 4 days ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Jan 2, 2025, 4:05 PM EST - 15 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 18, 2024, 8:00 AM EST - 4 weeks ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 6 weeks ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 7 weeks ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 20, 2024, 3:31 PM EST - 2 months ago

Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 14, 2024, 8:00 AM EST - 2 months ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 2 months ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 1:59 PM EST - 2 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 2 months ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Oct 22, 2024, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Oct 15, 2024, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

Oct 10, 2024, 8:00 AM EDT - 3 months ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Oct 7, 2024, 8:00 AM EDT - 3 months ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Sep 5, 2024, 8:00 AM EDT - 4 months ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Aug 26, 2024, 8:00 AM EDT - 5 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Aug 10, 2024, 1:00 AM EDT - 5 months ago

Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 5 months ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 8:00 AM EDT - 6 months ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Jul 11, 2024, 6:00 AM EDT - 6 months ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Jun 27, 2024, 8:18 AM EDT - 7 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jun 24, 2024, 8:58 AM EDT - 7 months ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

May 23, 2024, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 8 months ago

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

May 9, 2024, 10:54 AM EDT - 9 months ago

Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 9 months ago

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 2, 2024, 8:30 AM EDT - 9 months ago

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Apr 4, 2024, 5:56 PM EDT - 10 months ago

Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management

Mar 27, 2024, 8:45 PM EDT - 10 months ago

U.S. FDA approves Akebia's anemia drug

Mar 27, 2024, 8:26 PM EDT - 10 months ago

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Mar 14, 2024, 4:15 PM EDT - 11 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Mar 11, 2024, 5:05 PM EDT - 11 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Jan 30, 2024, 8:00 AM EST - 1 year ago

Akebia Secures $55 Million Term Loan Financing

Jan 9, 2024, 8:30 AM EST - 1 year ago

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Dec 20, 2023, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

Nov 8, 2023, 2:18 PM EST - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:30 AM EST - 1 year ago

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 5:52 PM EDT - 1 year ago

Akebia Therapeutics: Waiting For Round 2

Nov 2, 2023, 4:30 PM EDT - 1 year ago

Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights

Oct 25, 2023, 8:30 AM EDT - 1 year ago

Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

Oct 18, 2023, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aug 25, 2023, 11:25 AM EDT - 1 year ago

Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript

Aug 25, 2023, 8:09 AM EDT - 1 year ago

Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 24, 2023, 8:00 AM EDT - 1 year ago

Market Cap	421.09M
Revenue (ttm)	194.62M
Net Income (ttm)	-51.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	24.25
Profit Margin	-26.68%
Debt to Equity Ratio	-0.76

Volume	6,518,500
Avg Vol	2,305,052
Day's Range	N/A - N/A
Shares Out	218.18M
Stochastic %K	95%
Beta	0.72
Analysts	Strong Sell
Price Target	$5.50